Bass suffers another IPR setback

03-09-2015

Bass suffers another IPR setback

Dacian G / Shutterstock.com

Hedge fund manager Kyle Bass’s Coalition for Affordable Drugs has suffered another setback in its bid to knock out allegedly spurious patents after the US Patent and Trademark Office (USPTO) declined to institute an inter partes review (IPR) of a patent owned by Biogen.


Kyle Bass; Coalition for Affordable Drugs; PTAB; USPTO; Biogen; Tecfidera; MS

LSIPR